$518.39
0.12%
Nasdaq, Oct 02, 04:12 pm EDT. Closed.
ISIN
US45168D1046
Symbol
IDXX

IDEXX Laboratories Target price 2026 - Analyst rating & recommendation

IDEXX Laboratories Classifications & Recommendation

Buy
64%
Hold
36%

IDEXX Laboratories Price Target

Target Price $719.10
Price $518.39
Potential 38.72%
Number of Estimates 17
17 Analysts have issued a price target IDEXX Laboratories 2027 . The average IDEXX Laboratories target price is $719.10. This is 38.72% higher than the current stock price. The highest price target is $845.25 63.05% , the lowest is $477.17 7.95% .
A rating was issued by 22 analysts: 14 Analysts recommend IDEXX Laboratories to buy, 8 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the IDEXX Laboratories stock has an average upside potential 2027 of 38.72% . Most analysts recommend the IDEXX Laboratories stock at Purchase.

Sales and Margin forecast 2026, 2027 to 2033

Sign up for free to unlock analyst estimates. Sign up for free

Select at least one metric to display the chart.


Sep '25 Sep '26
Estimates
Revenue Billion $ 1.11 1.21
13.30% 9.75%
EBITDA Margin 35.42% 35.80%
2.22% 1.07%
Net Margin 24.85% 24.72%
4.10% 0.51%

19 Analysts have issued a sales forecast IDEXX Laboratories 2026 . The average IDEXX Laboratories sales estimate is

$4.8b
unlock
. This is
5.82% higher
unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$5.0b 9.46%
unlock
, the lowest is
$4.6b 1.29%
unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2025 $4.3b 10.42%
2026
$4.8b 11.95%
unlock
2027
$5.2b 8.76%
unlock
2028
$5.7b 8.78%
unlock
2029
$6.2b 8.98%
unlock
2030
$6.8b 9.42%
unlock
2031
$7.7b 13.96%
unlock
2032
$8.4b 8.38%
unlock
2033
$9.1b 7.98%
unlock

16 Analysts have issued an IDEXX Laboratories EBITDA forecast 2026. The average IDEXX Laboratories EBITDA estimate is

$1.7b
unlock
. This is
6.90% higher
unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
$1.9b 15.58%
unlock
, the lowest is
$1.6b 1.41%
unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2025 $1.5b 19.53%
2026
$1.7b 14.22%
unlock
2027
$1.9b 10.32%
unlock
2028
$2.1b 10.88%
unlock
2029
$2.3b 11.14%
unlock
2030
$2.6b 10.45%
unlock
2031
$3.1b 18.19%
unlock
2032
$3.4b 10.33%
unlock
2033
$3.7b 9.66%
unlock

EBITDA Margin

2025 35.07% 8.25%
2026
35.78% 2.02%
unlock
2027
36.30% 1.45%
unlock
2028
37.00% 1.93%
unlock
2029
37.73% 1.97%
unlock
2030
38.09% 0.95%
unlock
2031
39.50% 3.70%
unlock
2032
40.21% 1.80%
unlock
2033
40.84% 1.57%
unlock

19 IDEXX Laboratories Analysts have issued a net profit forecast 2026. The average IDEXX Laboratories net profit estimate is

$1.2b
unlock
. This is
4.73% higher
unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$1.3b 10.28%
unlock
, the lowest is
$1.1b 1.46%
unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2025 $1.1b 19.33%
2026
$1.2b 12.66%
unlock
2027
$1.3b 12.76%
unlock
2028
$1.5b 13.05%
unlock
2029
$1.7b 10.77%
unlock
2030
$1.9b 13.91%
unlock
2031
$2.4b 23.07%
unlock
2032
$2.6b 11.98%
unlock
2033
$2.9b 11.19%
unlock

Net Margin

2025 24.62% 8.06%
2026
24.77% 0.62%
unlock
2027
25.68% 3.67%
unlock
2028
26.69% 3.93%
unlock
2029
27.13% 1.65%
unlock
2030
28.25% 4.13%
unlock
2031
30.50% 7.96%
unlock
2032
31.52% 3.34%
unlock
2033
32.45% 2.95%
unlock

Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2033

Sign up for free to unlock analyst estimates. Sign up for free

Select at least one metric to display the chart.


Sep '25 Sep '26
Estimates
Earnings Per Share $ 3.40 3.80
21.43% 11.76%

19 Analysts have issued a IDEXX Laboratories forecast for earnings per share. The average IDEXX Laboratories EPS is

$15.13
unlock
. This is
5.36% higher
unlock
than earnings per share in the financial year 2025. The highest EPS forecast is
$15.94 11.00%
unlock
, the lowest is
$14.24 0.84%
unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2025 $13.08 22.59%
2026
$15.13 15.67%
unlock
2027
$17.06 12.76%
unlock
2028
$19.29 13.07%
unlock
2029
$21.37 10.78%
unlock
2030
$24.34 13.90%
unlock
2031
$29.96 23.09%
unlock
2032
$33.55 11.98%
unlock
2033
$37.30 11.18%
unlock

P/E ratio

Current 36.10 30.57%
2026
34.25 5.12%
unlock
2027
30.38 11.30%
unlock
2028
26.87 11.55%
unlock
2029
24.26 9.71%
unlock
2030
21.30 12.20%
unlock
2031
17.30 18.78%
unlock
2032
15.45 10.69%
unlock
2033
13.90 10.03%
unlock

Based on analysts' sales estimates for 2026, the IDEXX Laboratories stock is valued at an EV/Sales of

and an P/S ratio of .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 9.14 28.37%
2026
8.64 5.51%
unlock
2027
7.94 8.05%
unlock
2028
7.30 8.07%
unlock
2029
6.70 8.24%
unlock
2030
6.12 8.61%
unlock
2031
5.37 12.25%
unlock
2032
4.96 7.73%
unlock
2033
4.59 7.39%
unlock

P/S ratio

Current 8.97 28.40%
2026
8.48 5.50%
unlock
2027
7.79 8.05%
unlock
2028
7.16 8.07%
unlock
2029
6.57 8.24%
unlock
2030
6.01 8.61%
unlock
2031
5.27 12.25%
unlock
2032
4.86 7.73%
unlock
2033
4.51 7.39%
unlock

Current IDEXX Laboratories Upgrades & Downgrades

Analyst Rating Action Date
Barclays
Overweight
➜
Overweight
Unchanged Aug 11 2026
Citigroup
Neutral
➜
Neutral
Unchanged Aug 05 2026
UBS
Neutral
➜
Neutral
Unchanged Aug 05 2026
UBS
Neutral
➜
Neutral
Unchanged Jul 27 2026
UBS
Neutral
➜
Neutral
Unchanged Apr 28 2026
Citigroup
➜
Neutral
Initiated Apr 15 2026
Stifel
Buy
➜
Buy
Unchanged Mar 31 2026
Analyst Rating Date
Unchanged
Barclays:
Overweight
➜
Overweight
Aug 11 2026
Unchanged
Citigroup:
Neutral
➜
Neutral
Aug 05 2026
Unchanged
UBS:
Neutral
➜
Neutral
Aug 05 2026
Unchanged
UBS:
Neutral
➜
Neutral
Jul 27 2026
Unchanged
UBS:
Neutral
➜
Neutral
Apr 28 2026
Initiated
Citigroup:
➜
Neutral
Apr 15 2026
Unchanged
Stifel:
Buy
➜
Buy
Mar 31 2026

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today